End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.53 USD | -1.28% | +1.07% | +145.48% |
12/06 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
12/06 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+145.48% | 749M | |
+16.73% | 123B | |
+21.13% | 115B | |
+18.05% | 25.85B | |
-17.94% | 20.9B | |
-16.24% | 16.52B | |
-11.76% | 16.77B | |
-44.45% | 15.56B | |
+69.92% | 15.49B | |
+1.41% | 13.45B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate